IPP Bureau
Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr
By IPP Bureau - October 30, 2025
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
Granules India’s facility secures FDA EIR with 'VAI’
By IPP Bureau - October 30, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US
By IPP Bureau - October 30, 2025
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
By IPP Bureau - October 30, 2025
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test
By IPP Bureau - October 30, 2025
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
By IPP Bureau - October 30, 2025
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Quest Diagnostics’ study confirms accuracy of blood tests for Alzheimer’s disease diagnosis
By IPP Bureau - October 30, 2025
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Lilly and NVIDIA join forces to build world’s most powerful AI supercomputer for drug discovery
By IPP Bureau - October 30, 2025
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus
By IPP Bureau - October 30, 2025
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Allergan Aesthetics and Girls inspire the next generation of women leaders in STEM
By IPP Bureau - October 30, 2025
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes
By IPP Bureau - October 29, 2025
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
AskBio’s gene therapy shows promising 12-month results for heart failure
By IPP Bureau - October 29, 2025
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines
By IPP Bureau - October 29, 2025
FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma
By IPP Bureau - October 29, 2025
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain
By IPP Bureau - October 29, 2025
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
